Table 3.
SARS-CoV-2/COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy depending on antidiabetic therapy.
| Outcomes [presented as N (%)] | Antidiabetic medication | P | |
|---|---|---|---|
|
SGLT-2 inhibitors yes N = 1565 |
SGLT-2 inhibitors no N = 12,920 |
||
| SARS-CoV-2 infections | 188 (12.00%) | 2033 (15.70%) | < 0.001 |
| COVID-19 hospitalized | 58 (3.70%) | 1078 (8.30%) | < 0.001 |
| COVID-19 death | 17 (1.10%) | 353 (2.70%) | < 0.001 |
|
Metformin yes N = 9672 |
Metformin no N = 4813 |
||
| SARS-CoV-2 infections | 1440 (14.90%) | 781 (16.20%) | 0.035 |
| COVID-19 hospitalized | 679 (7.00%) | 457 (9.50%) | < 0.001 |
| COVID-19 death | 202 (2.10%) | 168 (3.50%) | < 0.001 |
|
Sulfonylureas yes N = 4953 |
Sulfonylureas no N = 9532 |
||
| SARS-CoV-2 infections | 783 (15.80%) | 1438 (15.10%) | 0.253 |
| COVID-19 hospitalized | 455 (9.20%) | 681 (7.10%) | < 0.001 |
| COVID-19 death | 144 (2.90%) | 226 (2.40%) | 0.058 |
|
DPP-4 inhibitors yes N = 3865 |
DPP-4 inhibitors no N = 10,620 |
||
| SARS-CoV-2 infections | 637 (16.50%) | 1584 (14.90%) | 0.021 |
| COVID-19 hospitalized | 324 (8.40%) | 812 (7.60%) | 0.151 |
| COVID-19 death | 107 (2.80%) | 263 (2.50%) | 0.341 |
|
GLP-1 analogues yes N = 909 |
GLP-1 analogues no N = 13,576 |
||
| SARS-CoV-2 infections | 142 (15.60%) | 2079 (15.30%) | 0.816 |
| COVID-19 hospitalized | 45 (5.00%) | 1091 (8.00%) | < 0.001 |
| COVID-19 death | 14 (1.50%) | 356 (2.60%) | 0.055 |
|
Acarbosis yes N = 52 |
Acarbosis no N = 7660 |
||
| SARS-CoV-2 infections | 10 (11.10%) | 2211 (15.40%) | 0.306 |
| COVID-19 hospitalized | 4 (4.40%) | 1132 (7.90%) | 0.322 |
| COVID-19 death | 2 (2.20%) | 368 (2.60%) | 1 |
|
Pioglitazone yes N = 552 |
Pioglitazone no N = 13,933 |
||
| SARS-CoV-2 infections | 93 (16.80%) | 2128 (15.30%) | 0.307 |
| COVID-19 hospitalized | 42 (7.60%) | 1094 (7.90%) | 0.927 |
| COVID-19 death | 12 (2.20%) | 358 (2.60%) | 0.680 |
|
Repaglinide yes N = 744 |
Repaglinide no N = 13,741 |
||
| SARS-CoV-2 infections | 111 (14.90%) | 2110 (15.40%) | 0.790 |
| COVID-19 hospitalized | 67 (9.00%) | 1069 (7.80%) | 0.233 |
| COVID-19 death | 24 (3.20%) | 346 (2.50%) | 0.231 |
|
Insulin yes N = 2341 |
Insulin no N = 12,144 |
||
| SARS-CoV-2 infections | 408 (17.40%) | 1813 (14.90%) | 0.002 |
| COVID-19 hospitalized | 222 (9.50%) | 914 (7.50%) | 0.001 |
| COVID-19 death | 86 (3.70%) | 284 (2.30%) | < 0.001 |
P calculated via hi square test.
Statistically significant p values are bolded.
Patient characteristics for each group are presented in Additional file 1.
SGLT-2 Sodium-glucose Cotransporter-2, DPP-4 Dipeptidyl Peptidase 4, GLP-1 Glucagon-like peptide 1.